INVEGA

LOE Approaching

paliperidone

NDAORALTABLET, EXTENDED RELEASE
Approved
Apr 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT04940039Phase 4Completed

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Started Jul 2021
93 enrolled
Schizophrenia
NCT04572685Phase 1Completed

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

Started Jan 2020
36 enrolled
Schizophrenia Patients
NCT04072575Phase 3Completed

A Study of Paliperidone Palmitate 6-Month Formulation

Started Sep 2019
178 enrolled
Schizophrenia
NCT03809325N/ACompleted

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Started Nov 2018
225 enrolled
Schizophrenia
NCT03713658Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Started Oct 2018
34 enrolled
Schizophrenia